Citations

Clear

215 citation(s) found for "Santo, C".

Distinguishing Malignant from Benign Causes of Breast Size Changes: A Case-based Primer for the Radiologist
Clark, Aurela , Conley, Hannah, Owen, Wendi A., Wang, Xiaoqin , George, Nanditha, Maimone, Santo , Letter, Haley , Shikoh, Fara , Szabunio, Margaret, Clark, Aurela I , Letter, Haley P, Shikoh, Fara Y , Maimone, Santo , Owen, Wendi A. , Szabunio, Margaret M.

Mayo Clinic

RadioGraphics | June 11, 2026 | Volume: 46 | Issue: 7 | Pages: No page available

10.1148/rg.250132 | PMID 42275243 Get It

Breast size changes are common, but the underlying cause may be challenging to diagnose and requires a structured approach combining patient history, physical examination, and multimodality imaging to differentiate benign from malignant causes and improve patient outcomes.
Efficacy and safety profile of volume-staged stereotactic radiosurgery for ruptured, large pediatric arteriovenous malformations: a multicenter cohort analysis
Tos, Salem M., Hajikarimloo, Bardia, Chan, Jason W., Sneed, Penny K. , McDermott, Michael W. , Seymour, Zachary , Grills, Inga, Reda, Wael A., Tawadros, Sameh R., Eldin, Reem Emad, Lunsford, L Dade, Niranjan, Ajay, Samanci, Yavuz, Lee, Cheng-chia, Yang, Huai-che, Sheehan, Darrah, Sheehan, Kimball, Liscak, Roman, Chytka, Tomáš , Alzate, Juan, Kondziolka, Douglas, Moreno, Nuria Martínez , Martínez‐Álvarez, Roberto , Hallan, David R , Fritch, Chanju, Jareczek, Francis, Sciscent, Bao Y., Mathieu, D, Carrier, Louis, Abdelsalam, Ahmed, Starke, Robert M., BENJAMIN, CAROLINA, Almeida, Timoteo, Singh, S.P., Lazo, Erwin, Chen, Ching-Jen, Esquenazi, Y., Becerril-Gaitan, Andrea, Blanco, Angel I., Palmer, Joshua D., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg N., Peterson, Jennifer L., Chiang, Veronica , Pikis, Stylianos , Xu, Zhiyuan, Sheehan, Jason P., Shinya, Yuki , Tos, Salem M , Hajikarimloo, Bardia , Mantziaris, Georgios , Chan, Jason , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Eldin, Reem M. Emad, Bin-Alamer, Othman , Lunsford, L. Dade , Niranjan, Ajay , Peker, Selçuk , Samancı, Yavuz , Lee, Cheng-chia, Yang, Huai‐Che , Sheehan, Darrah, Sheehan, Kimball , Liščák, Roman , Alzate, Juan Diego , Meng, Ying , Martinez-Álvarez, Roberto, Fritch, Chanju , Jareczek, Francis J. , Sciscent, Bao Y. , Mathieu, David , Abdelsalam, Ahmed , Starke, Robert M., Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Lazo, Erwin , Esquenazi, Yoshua , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Lanterna, Andrea Luigi, Bowden, Greg , Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2026.1.peds25593 | PMID 42284606 Get It

OBJECTIVE Ruptured, large pediatric arteriovenous malformations (AVMs) pose a significant management challenge due to high rerupture risk and the morbidity of conventional treatments. Volume-staged stereotactic radiosurgery (VS-SRS) has emerged as an alternative; however, evidence for its use in this specific population is limited. This study aimed to evaluate the long-term efficacy and safety of VS-SRS for ruptured, large AVMs in a dedicated pediatric cohort. METHODS This international, multicenter, retrospective cohort study from 21 centers analyzed outcomes for 42 pediatric patients (age < 18 years) with previously ruptured, large AVMs treated with VS-SRS. The primary outcome was complete AVM obliteration, and secondary outcomes included post-SRS hemorrhage, radiation-induced changes (RICs), and favorable outcome. Favorable outcome in this study was defined as obliteration without post-SRS hemorrhage or permanent RIC. RESULTS At the initial SRS, the median patient age was 14.5 years, and the median AVM volume was 15.0 cm 3 ; most AVMs were high grade (Spetzler-Martin grades IV and V). With a median follow-up of 41.5 months, complete AVM obliteration was achieved in 21 patients (50.0%). The cumulative obliteration rate was 37% at 5 years and 56% at 10 years. Patients with a nidus volume of ≤ 10 cm 3 had significantly higher cumulative obliteration rates than those with a nidus volume > 10 cm 3 (log-rank test, p = 0.021). Similarly, patients treated with a prescription dose > 17 Gy showed significantly higher cumulative obliteration rates compared to those treated with a dose ≤ 17 Gy (log-rank test, p = 0.012). The cumulative 5-year incidences of hemorrhage and RICs following VS-SRS were 19% and 7%, respectively. In multivariable analysis, only larger total AVM volume was an independent predictor of a lower likelihood of favorable outcome (hazard ratio 0.89, 95% CI 0.80–0.99; p = 0.036). CONCLUSIONS In this multicenter pediatric cohort, VS-SRS for ruptured, large AVMs provides a reasonable chance of long-term obliteration, but generally acceptable risks of post-SRS hemorrhage and RICs exist. VS-SRS should be considered as an option for pediatric patients with large, ruptured AVMs.
Patient Preferences for Result Communication Across the Breast Imaging Continuum: A Review
Maimone, Santo , Dodelzon, Katerina , Kendell, Anne Elizabeth , Coffey, Kristen , Maimone, Santo , Dodelzon, Katerina , Porembka, Jessica H.

Mayo Clinic

Journal of Breast Imaging | June 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbi/wbag037 | PMID 42497022 Get It

Abstract Patient preferences for communication of breast imaging results are heterogeneous and depend on the clinical context and perceived severity of findings. The 21st Century Cures Act, which mandates immediate electronic release of most medical records, has fundamentally altered result reporting and patient communication in breast imaging. Although this policy enhances transparency and timely access to information, it may conflict with established preferences for how patients receive screening mammography results, diagnostic evaluations, breast biopsy results, and breast cancer risk assessment information. Prior studies—largely conducted before widespread patient portal use—demonstrated that breast imaging patients consistently prioritize timely communication, while preferred delivery methods vary based on result acuity and emotional impact. However, much of this literature pre-dates implementation of the 21st Century Cures Act and widespread use of patient portals. This review examines the current literature to summarize evidence-based patient preferences for breast imaging result communication. As adoption of immediate result release continues to evolve across institutions, understanding contemporary patient preferences is essential to guiding radiologists in optimizing patient-centered communication strategies to inform best practices in breast imaging.
Management of High-Risk Breast Lesions: A Comprehensive Update
Zamora, Kathryn , Vorhis, Elizabeth B, Chikarmane, Sona A. , Coffey, Kristen , Dodelzon, Katerina , Evans, Madeline, Kendell, Anne Elizabeth , Maimone, Santo , Zhou, Wenhui, Bahl, Manisha , Zamora, Kathryn W , Komforti, Miglena K. , Coffey, Kristen , Dodelzon, Katerina , Maimone, Santo , Vorhis, Elizabeth, Porembka, Jessica H.

Mayo Clinic

Journal of Breast Imaging | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbi/wbag034 | PMID 42490060 Get It

Abstract High-risk breast lesions (HRLs) encompass a heterogeneous group of pathologies that coexist with an adjacent or synchronous malignancy, confer an increased risk of future breast cancer, or warrant surgical consideration because of upgrade potential or local behavior. Despite their clinical importance, management of HRLs remains variable. The American Society of Breast Surgeons (ASBrS) and the Society of Breast Imaging are collaborating to establish unified, evidence-based guidelines for managing these lesions. While these recommendations are currently in development, this review summarizes the existing literature and current guidance, including ASBrS recommendations, to provide context for multidisciplinary management. The article reviews the histopathologic features, imaging appearance, and management strategies for HRLs, including atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), flat epithelial atypia (FEA), papillomas with and without atypia, radial scar/complex sclerosing lesion (RS/CSL), mucocele-like lesion (MLL), desmoid tumor, and pseudoangiomatous stromal hyperplasia (PASH). Recent literature supports nonoperative management for specific radiologic-pathologic concordant lesions, particularly limited ADH, pure FEA, and pure RS, highlighting the important role of multidisciplinary discussion for personalized care. Lesions such as LCIS subtypes, papilloma with atypia, and MLL with atypia continue to warrant excision due to higher reported upgrade rates to malignancy. Beyond short-term management, HRLs such as ADH, ALH, and LCIS serve as biomarkers of long-term breast cancer risk, informing recommendations for surveillance, risk assessment, and chemoprevention counseling. Achieving a consensus among radiology, pathology, and surgical disciplines is essential to ensure oncologic safety while minimizing overtreatment in the era of precision breast care.
Comparison of High-Risk Breast Cancer Screenings with Concurrent Versus Staggered Breast MRI and Mammogram Schedules
Cornell, Lauren , Plante, Marie, Pai, Tanmayi, Li, Z, Maimone, Santo , Morozov, Andrey, Maxwell, Robert, Advani, Pooja, Robinson, Kristin, Li, Zhuo , Robinson, Kristin A. , Pai, Tanmayi , Cornell, Lauren F , Pai, Tanmayi Srinivas , Robinson, Kristin A , Maimone, Santo , Morozov, Andrey P, Maxwell, Robert W. , Advani, Pooja

Mayo Clinic

Journal of Clinical Medicine | June 2, 2026 | Volume: 15 | Issue: 11 | Pages: 4239

10.3390/jcm15114239 | PMID 42279102 Get It

Background: The current guidelines recommend that women at elevated risk for breast cancer (BC), defined as lifetime BC risk ≥ 20%, undergo annual screening with breast magnetic resonance imaging (MRI) and mammogram. However, limited evidence exists in the literature to guide the optimal timing of the MRI relative to the mammogram. Our study evaluated women undergoing high-risk BC screenings to determine the impact of timing for supplemental MRI on BC detection. Methods: Patients who completed high-risk screening MRI at a single institution from January 2019 through June 2022 were included. Baseline characteristics and clinical outcomes were collected through retrospective chart review. MRI exams were divided into two groups based on timing of MRI: concurrent (<90 days from mammogram) and staggered (≥90 days from mammogram). Results: Of 1115 patients initially identified, 770 met inclusion criteria, with a total of 3707 screening exams performed (2073 mammograms and 1634 MRIs). The final analysis included 1355 MRI exams for 712 patients, where a prior mammogram and MRI were available. Of the MRIs included, 784 (57.9%) were concurrent and 571 (42.1%) were staggered. Additional imaging was performed for 12.5% (98/784) of concurrent MRIs and 9.6% (55/571) of staggered MRIs. Biopsy rates were 9.8% (77/784) for concurrent and 7.0% (40/571) for staggered MRIs. In this high-risk population, there were surprisingly low BC detection rates, with a BC incremental detection rate of 0.5% in both the concurrent and staggered groups (p = 1.0), with the median size of detected invasive BCs equaling 5 mm in the concurrent group and 4 mm in the staggered group (p = 0.72). Conclusions: When comparing concurrent and staggered MRI regimens, there were no significant differences in incremental cancer detection rate, tumor size, rates of additional imaging, or negative biopsies. Further investigation with prospective analysis is needed to validate these findings.
Active surveillance versus stereotactic radiosurgery for Koos grade I and II vestibular schwannoma in patients aged 60 years or older
Ishaque, Mariam , Tos, Salem M., Hajikarimloo, Bardia, Fuentes, Angelica M. , Abou-Al-Shaar, Hussam, Peker, Selcuk, Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj, Schulder, Michael , Tourigny, Jean-Nicolas, Mathieu, D, Hamel, Andréanne, Briggs, Robert G., Yu, Cheng , Zada, Gabriel, Giannotta, S L, Palque, Sarai, Kumar, S Praveen, Kumar, Narendra, Rogowski, Brandon, Shepard, Matthew J., Trifiletti, Daniel M., Dayawansa, Sam, Vasconcellos, Fernando De Nigris, Bernstein, Kenneth , Schnurman, Zane, Alzate, Juan, Kondziolka, Douglas, Sheehan, Jason P., Johnson, Bryan A, Mantziaris, Georgios , Tos, Salem M , Hajikarimloo, Bardia , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Peker, Selçuk , Samancı, Yavuz , Goenka, Anuj , Mathieu, David , Zada, Gabriel , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kaur, Rupinder , Rogowski, Brandon, Johnson, Bryan A., Trifiletti, Daniel M. , Warnick, Ronald E. , Dayawansa, Sam , Mashiach, Elad , Vasconcellos, Fernando De Nigris , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas, Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery | May 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2026.1.jns242756 | PMID 42139729 Get It

OBJECTIVE The aim of this study was to evaluate freedom from tumor progression and clinical outcomes in older adults with small- to medium-sized vestibular schwannoma (VS) managed by observation versus stereotactic radiosurgery (SRS) to better inform optimal management in this patient population. METHODS In this international multicenter study, patients aged ≥ 60 years with Koos grade I or II VS managed by observation or SRS were retrospectively reviewed. Propensity score matching was conducted using patient characteristics, tumor size, and hearing assessments. Outcome measures of freedom from tumor progression, serviceable hearing preservation (SHP), and neurological function (tinnitus, vestibulopathy, House-Brackmann grade, and trigeminal nerve function) were assessed for both groups. RESULTS The observation and SRS groups each comprised 51 matched patients (median age 68 years for both). Ipsilateral serviceable hearing was observed at presentation for 35 patients in each group. The median follow-up duration was 39 months in the observation group versus 27 months in the SRS group (p = 0.5). Tumor progression was significantly lower with SRS than with observation (2% vs 52.9%, p < 0.001). The rate of 5-year freedom from tumor progression was 100% in the SRS group versus 43% (95% CI 29%–64%) in the observation group. The rate of 10-year freedom from tumor progression was 90% (95% CI 73%–100%) in the SRS group versus 20% (95% CI 8.5%–49%) in the observation group. At the last follow-up, hearing loss occurred in 42.9% of the observation group and 51.4% of those who underwent SRS (p = 0.5). The 3-year SHP rate was 68% (95% CI 53%–88%) versus 65% (95% CI 49%–85%) (p = 0.8), and the 5-year SHP rate was 53% in both groups (95% CI 36%–78% in the observation group and 95% CI 35%–79% in the SRS group, p = 0.8). The composite endpoint of tumor progression and/or worsened neurological outcome, including hearing loss, tinnitus, vestibulopathy, facial nerve dysfunction (House-Brackmann grade), or trigeminal dysfunction, demonstrated a significantly lower rate in the SRS group (17.6%) compared with the observation group (66.7%) (p < 0.001). CONCLUSIONS SRS in older patients for management of Koos grade I or II VS resulted in significantly superior rates of freedom from tumor progression, comparable hearing preservation rates, and significantly higher rates of favorable overall radiographic and neurological outcomes than observation alone. Compared with observation, SRS might be the preferred management option in this patient population.
Efficacy and safety of aspirin for primary prevention in adults with elevated lipoprotein(a) or genetic susceptibility via LPA gene variants: a systematic review and meta-analysis
Lopes, Rodolfo Alves, Vergara‐Sanchez, Carlos , TEJEDA, ALFREDO PEREZ TAGLE, Khorsandi, Jordan , Fukunaga, Christian Ken , Katsuyama, Eric , Talavera, Juan Armando , Yang, Eugene , Shapiro, Michael D. , Yang, Eugene , Lopes, Rodolfo A , Vergara Sanchez, Carlos A , Perez Tagle Tejeda, Alfredo , Ken Fukunaga, Christian , Shapiro, Michael D

Mayo Clinic

European Journal of Preventive Cardiology | April 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwag207 | PMID 42138694 Get It

Abstract Aims Routine aspirin use for primary prevention yields modest cardiovascular benefit but increases bleeding risk in average-risk adults. Whether individuals with elevated lipoprotein(a) [Lp(a)] levels or high-risk LPA variants derive greater benefit remains uncertain. Methods and results Following Cochrane and PRISMA guidelines, we systematically searched PubMed/MEDLINE, Embase, and Cochrane Central for studies of adults without ASCVD, elevated Lp(a) (≥50 mg/dL), high-risk LPA genotypes, or elevated genetic risk scores, comparing aspirin vs. no aspirin use. Random-effects meta-analyses using restricted maximum-likelihood (REML) estimation with Hartung–Knapp–Sidik–Jonkman (HKSJ) adjustment were used to pool hazard ratios (HR) and 95% confidence intervals (CI). In six studies, 6628 participants were included. Pooled random effects showed no significant reduction in major adverse cardiovascular events (MACE) with aspirin (HR = 0.60; 95% CI 0.31–1.17; P = 0.1) or clinical bleeding events (HR = 1.24; 95% CI 0.83–1.87; P = 0.18). Subgroup analyses showed a nonsignificant reduction MACE among elevated Lp(a) (HR = 0.63; 95% CI 0.16 to 2.49; P = 0.284) and statistically significant reduction among LPA rs3798220 carriers (HR = 0.37; 95% CI 0.19 to 0.71; P = 0.003), though this finding was not consistent in the sensitivity analyses. Conclusion Among adults without ASCVD but with elevated Lp(a) or high-risk LPA genotypes, aspirin use did not confer a statistically significant cardiovascular benefit and was associated with numerically higher bleeding risk. The apparent reduction seen in rs3798220 carriers was inconsistent and likely reflects small-sample bias.
Imaging Features and Risk Factors Associated with Locoregional Recurrence of Breast Cancer: Insights for Imaging and Clinical Practice
Clark, Aurela , Shikoh, Fara , Letter, Haley , Maimone, Santo , Letter, Haley P, Maimone, Santo , Clark, Aurela I

Mayo Clinic

Journal of Breast Imaging | March 25, 2026 | Volume: 8 | Issue: 3 | Pages: 318-337

10.1093/jbi/wbag006 | PMID 42161482 Get It

Abstract Women with a personal history of breast cancer (PHBC) remain at risk for ipsilateral breast tumor recurrence or a second primary tumor, with a cumulative incidence of 14.3% and reported annual risk of approximately 1–2%. Post-treatment changes can obscure imaging findings, making early recognition of recurrence a challenging, but critical skill for breast radiologists. Detection of early breast cancer recurrence, before it becomes symptomatic, is linked to improved survival, highlighting the need for multimodality surveillance imaging. This review summarizes key prognostic factors that influence recurrence risk and should inform imaging interpretation. Incorporating these prognostic factors into practice can aid imaging interpretation by heightening the attention to subtle changes that may reflect early recurrence. Illustrative cases are used to demonstrate the imaging spectrum of locoregional recurrence in post-lumpectomy and post-mastectomy patients. Recurrences often resemble the imaging features of the primary tumor but may also present subtly. The distinction between recurrence and benign post-treatment change is emphasized, with attention to imaging findings that warrant further evaluation. Finally, emerging evidence-based recommendations for risk-adapted surveillance incorporating tumor biology, receptor status, and stage are reviewed to support early detection and improved outcomes
2026 Latin American consensus for the management of patients with hypertension and cardio-renal and metabolic disturbances: endorsed by the Latin American Society of Hypertension, the Iberoamerican Hypertension League, and the World Hypertension League
Coca, António , Sanchez, Ramiro , Salazar, Dora I. Molina De, Peñaherrera, Ernesto , Alcocer, Luis, Barbosa, Eduardo, Grassi, Guido, Lopez-Jaramillo, Patricio, Lurbe, E, Parra-Carrillo, José, Ramírez, Agustín, Redón, Josep, Sebba-Barroso, Weimar, Acosta, Andres, Aristizábal, Dagnóvar, Bryce, Alfonso, Cerezo, Gustavo, COHEN, RICARDO V., Diaz-Velasco, Margarita E., Hernández, Rafael, Lanas, Fernando, Machado, Livia, Musso, Carla, Piskorz, Daniel, Ponte-Negreti, Carlos I., Ramos, Olga, Sánchez, María J., Valdez, Osiris, Vicario, Augusto, Villar, Raul, Parati, Gianfranco, Whelton, Paul K., Wyss, Fernando, Mancia, Giuseppe, SALAZAR, DORA INES MOLINA DE, Grassi, Guido M. , López‐Jaramillo, Patricio , Lurbe, Empar , Parra-Carrillo, José Z., Redón, Josep , Sebba-Barroso, Weimar K., Cerezo, Gustavo Hernán, COHEN, RICARDO VITOR , Diaz-Velazco, Margarita E., Hernández, Rafael Hernández, Laņas, Fernando , Piskorz, Daniel , Ponte-Negretti, Carlos Ignacio , Sanchez, María J., Valdez-Tiburcio, Osiris , Villar, Raúl , Parati, Gianfranco , Whelton, Paul K. , Mancia, Giuseppe

Mayo Clinic

Journal of Hypertension | March 24, 2026 | Volume: 44 | Issue: 6 | Pages: 885-910

10.1097/hjh.0000000000004290 | PMID 41875318 Get It

Hypertension is the main risk factor for cardiovascular disease (CVD), affecting 20–40% of Latin American (LATAM) adults, and responsible for more than two million deaths annually due to CVD. The different ethnic, economic, geographic, and cultural characteristics of the LATAM population influence the high prevalence of all cardiovascular risk factors (CVRF), particularly metabolic disturbances such as type 2 diabetes (DM2), obesity and the metabolic syndrome. Their main determinants in LATAM includes environment, food quality, social inequity, low education, political aspects, contextual behaviour, and genetics. The prevalence of overweight and obesity in LATAM increased during the last four decades reaching figures of 10–20% in childhood, 30–40% in adolescence, and 60–70% in adults. Many studies in the region have reported the extremely low rates of awareness, treatment, and control of CVRF in the general population of LATAM, particularly in patients with metabolic disorders, and the consequent high cardiovascular morbidity and mortality. This 2026 LATAM consensus is developed by a large group of experts from different LATAM countries, the USA and Europe, representing areas of internal medicine, cardiology, nephrology, endocrinology, geriatrics, paediatrics, pharmacology, and epidemiology. A careful search for novel studies in LATAM, together with new evidence that has emerged since the 2019 LATAM consensus, support the statements and recommendations in the current report. This update aims to provide clear and useful recommendations for health professionals to improve awareness, treatment, and control of hypertension and associated CVRF in the region.
Abstract PD4-02: An AI algorithm for breast cancer detection improves future BC risk prediction among women with benign breast disease
Vachon, C. M., Winham, S., Jensen, M., Hursh, D., Norman, A., Fischer, Jessica, Schrup, S., Seymour, L., Gehling, Denice, Nyante, S., Troester, M. A., Karssemeijer, Nico , Vierkant, R., Radisky, D., Scott, C., Maimone, S. I., Degnim, Amy C., Sherman, M. E., Jensen, Michael A. , Pacheco-Spann, Laura M. , Norman, Aaron D. , Seymour, Lisa R. , Nyante, Sarah J. , Vierkant, Robert A. , Radisky, Derek C. , Maimone, Santo , Degnim, Amy C. , Sherman, Mark E.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD4-02-PD4-02

10.1158/1557-3265.sabcs25-pd4-02 Get It

Abstract Background: Artificial intelligence (AI) algorithms based on deep learning approaches show promise in improving breast cancer (BC) detection on mammography and may also improve prediction of future BC risk compared with clinical risk prediction models. Historical clinical risk prediction models underperform among women with BBD; however, AI models for BC detection on mammography have not been tested among women at elevated BC risk due to benign breast disease (BBD). We evaluated if an AI cancer detection algorithm can aid BC risk prediction among women with BBD. Methods: We examined women without a prior BC who had an initial BBD biopsy at Mayo Clinic, Rochester, between 2002 and 2013. Incident BC occurring after BBD was identified using the Mayo Tumor Registry and supplemented by follow-up questionnaires. Only women with a full field digital mammogram at least 2 years prior to BC diagnosis were eligible. A breast pathologist evaluated BBD according to increasing severity, as non-proliferative (NP), proliferative disease without atypia (PDWA) or atypical hyperplasia (AH). AI malignancy scores derived from the Transpara detection algorithm (1-10) and volumetric percent density (VPD) from Volpara (per one standard deviation, SD) were assessed from mammograms close to BBD diagnosis. Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) with 95% Confidence Intervals (CIs), adjusted for age and BMI. C-statistics were estimated to assess the contribution of each factor to BC risk prediction. Likelihood ratio tests (LRTs) and bootstrapping methods were used to compare model performance with the addition of AI malignancy score. Results: The BBD cohort with mammography consisted of 3,125 women followed for a median 12.9 years, with 250 incident BC. Of these, 221 BC occurred at least two years after the mammogram and were used in analyses. As expected, increased BC risk was associated with BBD severity [for AH HR=3.18 (95%CI: 2.04, 4.95) and for PDWA HR=1.59 (95%CI: 1.17, 2.14) compared to NP] and with higher VPD [HR=1.24 per SD (95% CI: 1.05, 1.45)] (Table ). The AI-malignancy score alone was also associated with BC risk [HR=1.16 per 1 unit score (95%CI: 1.09,1.23)] and showed similar discriminatory accuracy [C-statistic=0.626 (95%CI: 0.586, 0.665)] as the model with BBD severity and VPD combined [C-statistic=0.627, (95%CI: 0.585, 0.669)] (Table ). In models with BBD severity and VPD, the AI-malignancy score was an independent risk factor for BC [HR=1.14 (95%CI: 1.07, 1.21); PLRT&lt;0.001] but only achieved a marginally significant improvement in discriminatory accuracy [C-statistic=0.651 (0.609, 0.693), ΔC-statistic=0.024 (95% CI: 0.000, 0.047)]. Conclusion: In this preliminary study, an AI BC detection algorithm achieved similar performance in predicting future BC risk compared to established risk factors. Citation Format: C. M. Vachon, S. Winham, M. Jensen, D. Hursh, L. Pacheco-Spann, A. Norman, J. Fischer, S. Schrup, L. Seymour, D. Gehling, S. Nyante, M. Troester, N. Karssemeijer, R. Vierkant, D. Radisky, C. Scott, S. I. Maimone, A. Degnim, M. Sherman. An AI algorithm for breast cancer detection improves future BC risk prediction among women with benign breast disease [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD4-02.